Item 16. FORM 10-K SUMMARY

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, Abbott Laboratories has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


			ABBOTT LABORATORIES

			By			/s/ ROBERT B. FORD
						Robert B. Ford
						Chairman of the Board and Chief Executive Officer

			Date:			February 20, 2026

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of Abbott Laboratories on February 20, 2026 in the capacities indicated below.


/s/ ROBERT B. FORD						/s/ PHILIP P. BOUDREAU
Robert B. Ford						Philip P. Boudreau
Chairman of the Board and Chief Executive Officer, and Director of Abbott Laboratories (principal executive officer)						Executive Vice President, Finance and Chief Financial Officer (principal financial officer)

/s/ JOHN A. MCCOY, JR.
John A. McCoy, Jr.
Vice President, Finance and Controller (principal accounting officer)

/s/ NITA AHUJA						/s/ ROBERT J. ALPERN
Nita Ahuja, M.D.						Robert J. Alpern, M.D.
Director of Abbott Laboratories						Director of Abbott Laboratories

/s/ CLAIRE BABINEAUX-FONTENOT						/s/ SALLY E. BLOUNT
Claire Babineaux-Fontenot						Sally E. Blount, Ph.D.
Director of Abbott Laboratories						Director of Abbott Laboratories

/s/ PAOLA GONZALEZ						/s/ MICHELLE A. KUMBIER
Paola Gonzalez						Michelle A. Kumbier
Director of Abbott Laboratories						Director of Abbott Laboratories

/s/ DARREN W. MCDEW						/s/ NANCY MCKINSTRY
Darren W. McDew						Nancy McKinstry
Director of Abbott Laboratories						Director of Abbott Laboratories

/s/ MICHAEL G. O'GRADY						/s/ MICHAEL F. ROMAN
Michael G. O'Grady						Michael F. Roman
Director of Abbott Laboratories						Director of Abbott Laboratories

/s/ DANIEL J. STARKS						/s/ JOHN G. STRATTON
Daniel J. Starks						John G. Stratton
Director of Abbott Laboratories						Director of Abbott Laboratories

ABBOTT LABORATORIES AND SUBSIDIARIES

SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS

FOR THE YEARS ENDED DECEMBER 31, 2025, 2024, AND 2023

(in millions)


Allowances for Doubtful Accounts and Product Returns	Balance at Beginning of Year		Provisions/ Charges to Income		Amounts Charged Off and Other Deductions		Balance at End of Year
2025	$	439	$	139	$	(88)	$	490
2024	444		113		(118)		439
2023	500		60		(116)		444

Report of Independent Registered Public Accounting Firm

To the Shareholders and the Board of Directors of Abbott Laboratories

We have audited the consolidated financial statements of Abbott Laboratories and subsidiaries (the Company) as of December 31, 2025 and 2024, for each of the three years in the period ended December 31, 2025, and have issued our report thereon dated February 20, 2026 (included elsewhere in this Annual Report on Form 10-K). Our audits of the consolidated financial statements included the financial statement schedule listed in Item 15(a)(2) of this Annual Report on Form 10-K (the “schedule”). This schedule is the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s schedule, based on our audits.

In our opinion, the schedule presents fairly, in all material respects, the information set forth therein when considered in conjunction with the consolidated financial statements.

/s/ Ernst & Young LLP

Chicago, Illinois

February 20, 2026

Previous: Item 15. EXHIBIT AND FINANCIAL STATEMENT SCHEDULES